journal article·2024-10Open access

Hypoxic Upregulation of IER2 Increases Paracrine GMFG Signaling of Endoplasmic Reticulum Stress‐CAF to Promote Chordoma Progression via Targeting ITGB1

Tao‐Lan Zhang, Bo‐Wen Zheng, Chao Xia, Peng‐Fei Wu, Bo‐Yv Zheng, Ling‐Xiang Jiang, Jing Li, Guo‐Hua Lv, Hong Zhou, Wei Huang, Ming‐Xiang Zou

Advanced Science· Volume 11· Issue 40

Abstract

Abstract Currently, the oncogenic mechanism of endoplasmic reticulum stress‐CAF (ERS‐CAF) subpopulation in chordoma remains unknown. Here, single‐cell RNA sequencing, spatial transcriptomics, GeoMx Digital Spatial Profiler, data‐independent acquisition proteomics, bulk RNA‐seq, and multiplexed quantitative immunofluorescence are used to unveil the precise molecular mechanism of how ERS‐CAF affected chordoma progression. Results show that hypoxic microenvironment reprograms CAFs into ERS‐CAF subtype. Mechanistically, this occurrs via hypoxia‐mediated transcriptional upregulation of IER2. Overexpression of IER2 in CAFs promotes chordoma progression, which can be impeded by IER2 knockdown or use of ERS inhibitors. IER2 also induces expression of ERS‐CAF marker genes and results in production of a pro‐tumorigenic paracrine GMFG signaling, which exert its biological function via directly binding to ITGB1 on tumor cells. ITGB1 inhibition attenuates tumor malignant progression, which can be partially reversed by exogenous GMFG intervention. Further analyses reveal a positive correlation between ITGB1high tumor cell counts and SPP1+ macrophage density, as well as the spatial proximity of these two cell types. Clinically, a significant correlation of high IER2/ITGB1 expression with tumor aggressive phenotype and poor patient survival is observed. Collectively, the findings suggest that ERS‐CAF regulates SPP1+ macrophage to aggravate chordoma progression via the IER2/GMFG/ITGB1 axis, which may be targeted therapeutically in future.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Proteoglycans and glycosaminoglycans research · Cell Adhesion Molecules Research · Bone Tumor Diagnosis and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacy The First Affiliated Hospital Hengyang Medical School University of South China Hengyang 421001 China

Musculoskeletal Tumor Center Peking University People's Hospital Peking University Beijing 100044 China

Department of Spine Surgery The First Affiliated Hospital Hengyang Medical School University of South China Hengyang 421001 China

Department of Genetics and Endocrinology National Children's Medical Center for South Central Region Guangzhou Women and Children's Medical Center Guangzhou Medical University Guangzhou Guangdong 510623 China

Department of Orthopedics Surgery General Hospital of the Central Theater Command Wuhan 430061 China

Department of Radiation Oncology Melvin and Bren Simon Comprehensive Cancer Center Indiana University School of Medicine Indianapolis IN 46202 USA

Department of Spine Surgery The Second Xiangya Hospital Central South University Changsha 410011 China

Department of Radiology The First Affiliated Hospital Hengyang Medical School University of South China Hengyang 421001 China

The First Affiliated Hospital Health Management Center Hengyang Medical School University of South China Hengyang 421001 China

Funding

National Natural Science Foundation of China · China Scholarship Council · Natural Science Foundation of Hunan Province

References (48)

Show source-provided references
1. 10.1016/S1470-2045(14)71190-810.1016/S1470-2045(14)71190-8 ↗
2. 10.1016/S1470-2045(11)70337-010.1016/S1470-2045(11)70337-0 ↗
3. 10.1016/j.ejca.2017.06.03810.1016/j.ejca.2017.06.038 ↗
4. 10.1093/neuonc/nou33110.1093/neuonc/nou331 ↗
5. 10.1186/s13046-021-02037-y10.1186/s13046-021-02037-y ↗
6. 10.1093/neuros/nyz33310.1093/neuros/nyz333 ↗
7. 10.1007/s00262-022-03152-110.1007/s00262-022-03152-1 ↗
8. 10.1093/neuonc/noad17310.1093/neuonc/noad173 ↗
9. 10.1016/j.cell.2007.04.01910.1016/j.cell.2007.04.019 ↗
10. 10.1016/j.semcancer.2015.04.01010.1016/j.semcancer.2015.04.010 ↗
11. 10.1186/s13046-020-01824-310.1186/s13046-020-01824-3 ↗
12. 10.1021/acs.jmedchem.1c0124810.1021/acs.jmedchem.1c01248 ↗
13. 10.1016/j.biopha.2023.11476210.1016/j.biopha.2023.114762 ↗
14. 10.1158/0008-5472.CAN-19-310810.1158/0008-5472.CAN-19-3108 ↗
15. 10.1038/s41568-020-00312-210.1038/s41568-020-00312-2 ↗
16. 10.1038/onc.2011.53510.1038/onc.2011.535 ↗
17. 10.1038/s41388-021-02027-610.1038/s41388-021-02027-6 ↗
18. 10.1016/j.cellsig.2018.12.01210.1016/j.cellsig.2018.12.012 ↗
19. 10.1007/s13402-021-00617-w10.1007/s13402-021-00617-w ↗
20. 10.1038/nrc372610.1038/nrc3726 ↗
21. 10.1038/nri.2016.6210.1038/nri.2016.62 ↗
22. 10.1016/j.tibs.2015.01.00210.1016/j.tibs.2015.01.002 ↗
23. 10.1186/s12943-019-0994-210.1186/s12943-019-0994-2 ↗
24. 10.1016/j.ccell.2022.11.00510.1016/j.ccell.2022.11.005 ↗
25. 10.1126/science.ade229210.1126/science.ade2292 ↗
26. 10.1038/s41467-022-29366-610.1038/s41467-022-29366-6 ↗
27. 10.1136/jitc-2024-00931310.1136/jitc-2024-009313 ↗
28. 10.1093/neuros/nyy27410.1093/neuros/nyy274 ↗
29. 10.1016/j.trecan.2019.08.00510.1016/j.trecan.2019.08.005 ↗
30. 10.1016/j.ajpath.2020.01.01010.1016/j.ajpath.2020.01.010 ↗
31. 10.1016/j.trecan.2022.06.00610.1016/j.trecan.2022.06.006 ↗
32. 10.1016/j.cbd.2017.05.00310.1016/j.cbd.2017.05.003 ↗
33. 10.26508/lsa.20180011310.26508/lsa.201800113 ↗
34. 10.1186/s13287-021-02498-010.1186/s13287-021-02498-0 ↗
35. 10.1016/j.ijbiomac.2018.01.12710.1016/j.ijbiomac.2018.01.127 ↗
36. 10.1016/j.addr.2022.11450410.1016/j.addr.2022.114504 ↗
37. 10.1038/ncomms447210.1038/ncomms4472 ↗
38. 10.1161/01.RES.0000237662.23539.0b10.1161/01.RES.0000237662.23539.0b ↗
39. 10.1016/j.yexcr.2013.01.00410.1016/j.yexcr.2013.01.004 ↗
40. 10.1016/j.ygyno.2014.01.04410.1016/j.ygyno.2014.01.044 ↗
41. 10.3389/fonc.2021.62963310.3389/fonc.2021.629633 ↗
42. 10.1136/gutjnl-2015-30932210.1136/gutjnl-2015-309322 ↗
43. 10.1002/ijc.3085410.1002/ijc.30854 ↗
44. 10.1074/jbc.M115.67420010.1074/jbc.M115.674200 ↗
45. 10.1172/JCI4581710.1172/JCI45817 ↗
46. 10.1158/0008-5472.CAN-21-384010.1158/0008-5472.CAN-21-3840 ↗
47. 10.1002/ctm2.410.1002/ctm2.4 ↗
48. 10.1093/neuonc/noae00710.1093/neuonc/noae007 ↗